nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

8. Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden

verfasst von : Prof. Dr. med. Dipl. Psych. Susanne Walitza, Dr. rer. nat. Lukasz Smigielski, Prof. Dr. rer. nat. Manfred Gerlach

Erschienen in: Neuro-/Psychopharmaka im Kindes- und Jugendalter

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Als Psychostimulanzien oder Stimulanzien wird die Gruppe von Neuro‑/Psychopharmaka bezeichnet, die vorwiegend eine erregende Wirkung auf das zentrale Nervensystem und die Psyche ausüben. Das Hauptanwendungsgebiet der Psychostimulanzien Methylphenidat und Amphetamin ist die Therapie der Aufmerksamkeitsdefizit‑/Hyperaktivitätsstörung (ADHS). Weitere Wirkstoffe zur Behandlung der ADHS sind Atomoxetin und Guanfacin, die als Nicht-Psychostimulanzien eingeordnet werden. In diesem Kapitel werden die Wirk(ungs)mechanismen dieser Wirkstoffe besprochen und schwerpunktmäßig diejenigen pharmakologischen Aspekte dargestellt, die für Kliniker für den therapeutischen Einsatz dieser Substanzen relevant sind. Dabei wird u. a. auf Anwendungsgebiete, die klinische Wirksamkeit und die Studienlage eingegangen. Es werden Dosierungsempfehlungen gegeben und mögliche unerwünschte Arzneimittelwirkungen und -wechselwirkungen behandelt. Das Kapitel schließt mit Empfehlungen zur Behandlungsdauer sowie zu notwendigen Kontrolluntersuchungen im Rahmen der ADHS-Pharmakotherapie.

AACAP Official Action (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Psy 41(Suppl 2):26S–49S

AACAP Official Action (2007) Practise parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Child Psy 46:894–921CrossRef

AWMF (2018) (S3) Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“. AWMF-Register Nr. 028-045. https://www.awmf.org/leitlinien/detail/ll/028-045.html. Zugegriffen: 30. Okt. 2021

Ahmann PA, Theye FW, Berg R et al. (2001) Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics 107:E10PubMedCrossRef

Albin RL (2006) Neurobiology of basal ganglia and Tourette syndrome: Striatal and dopamine function. Adv Neurol 99:99–106PubMed

Allen A, Kurlan R, Gilbert D et al. (2005) Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65:1941–1949PubMedCrossRef

Arnold LE (2000) Methylphenidate versus amphetamine: a comparative review. In: Greenhill LL, Osman BB (Hrsg) Ritalin, theory and practice. Mary Ann Liebert, New Rochelle, S 127–139

Arnsten AF (2020) Guanfacine’s mechanism of action in treating prefrontal cortical disorders: successful translation across species. Neurobiol Learn Memory 176:107327CrossRef

Arnsten AF, Scahill L, Findling RL (2007) Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adol Psychop 17:393–406CrossRef

Arzneimittel-Kompendium der Schweiz (2014) Standardwerk mit den offiziellen Fachinformationen. Documed, Basel

Aster HC, Romanos M, Walitza S et al. (2022) Responsivity of the striatal dopamine system to methylphenidate. A within-subject I-123-beta-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder. Front Psychiatry. https://doi.org/10.3389/fpsyt.2022.804730CrossRefPubMedPubMedCentral

Baird AL, Coogan AN, Kaufling J, Barrot M, Thome J (2013) Daily methylphenidate and atomoxetine treatment impacts on clock gene protein expression in the mouse brain. Brain Res 1513:61–71PubMedCrossRef

Banaschewski T, Coghill D, Santosh P et al. (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adoles Psy 15:476–495CrossRef

Bangs ME, Jin L, Zhang S et al. (2008) Hepatic events associated with atomoxetine treatment for attention deficit hyperactivity disorder. Drug Saf 31:345–354PubMedCrossRef

Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK (2014) Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adol Psychopharmacol 24:426–434CrossRef

Bari A, Xu S, Pignatelli M et al. (2020) Differential attentional control mechanisms by two distinct noradrenergic coeruleo-frontal cortical pathways. Proc Nat Acad Sci Usa 117:29080–29089PubMedPubMedCentralCrossRef

Barton J (2005) Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 90(Suppl 1):i26–i29PubMedPubMedCentralCrossRef

Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:E201–E205CrossRef

Biederman J, Melmed RD, Patel A et al. (2008a) A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121:e73–e84PubMedCrossRef

Biederman J, Monuteaux MC, Spencer T et al. (2008b) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: A naturalistic controlled 10-year follow-up study. Am J Psychiat 165:597–603PubMedCrossRef

Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF (2009) Meta-analysis: treatment of attention-deficit /hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Psy 48:884–893CrossRef

Boedhoe PS, Van Rooij D, Hoogman M et al. (2020) Subcortical brain volume, regional cortical thickness, and cortical surface area across disorders: Findings from the ENIGMA ADHD, ASD, and OCD working groups. Am J Psychiatry 177:834–843PubMedPubMedCentralCrossRef

Boland H, DiSalvo M, Fried R et al. (2020) A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res 123:21–30PubMedCrossRef

Bonvicini C, Cortese S, Maj C et al. (2020) DRD4 48 bp multiallelic variants as age-population-specific biomarkers in attention-deficit/hyperactivity disorder. Transl Psychiatry 10:1–19CrossRef

Bouziane C, Filatova OG, Schrantee A et al. (2019) White matter by diffusion MRI following methylphenidate treatment: a randomized control trial in males with attention-deficit/hyperactivity disorder. Radiology 293:186–192PubMedCrossRef

Bradley C (1937) The behavior of children receiving Benzedrine. Am J Psychiat 94:577–585CrossRef

Brem S, Grünblatt E, Drechsler R, Riederer P, Walitza S (2014) The neurobiological linke between OCD and ADHD. Atten Defic Hyperact Disord 6:175–202PubMedPubMedCentralCrossRef

Brikell I, Chen Q, Kuja-Halkola R et al. (2019) Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia 60:284–293PubMedPubMedCentralCrossRef

Broese M, Riemann D, Hein L, Nissen C (2012) alpha-Adrenergic receptor function, arousal and sleep: mechanisms and therapeutic implications. Pharmacopsychiatry 45:209–216PubMedCrossRef

Brown JT, Bishop JR, Sangkuhl K et al. (2019) Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP) 2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther 106:94–102PubMedCrossRef

Buitelaar JK, Danckaerts M, Gillberg C et al. (2004) A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adoles Psy 13:249–257CrossRef

Buitelaar JK, Michelson D, Danckaerts M et al. (2007) A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 61:694–699PubMedCrossRef

Bushe CJ, Savill NC (2014) Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safety. J Psychopharmacol 28:204–211PubMedCrossRef

Bymaster FP, Katner JS, Nelson DL et al. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacol 27:699–711CrossRef

Carucci S, Balia C, Gagliano A et al. (2021) Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neurosc Biobehav Rev 120:509–505CrossRef

Castells X, Ramon M, Cunill R, Olivé C, Serrano D (2021) Relationship between treatment duration and efficacy of pharmacological treatment for ADHD: a meta-analysis and meta-regression of 87 randomized controlled clinical trials. J Atten Disord 25(10):1352–1361PubMedCrossRef

Chang Z, Lichtenstein P, Halldner L et al. (2014) Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry 55:878–885PubMedCrossRef

Charach A, Yeung E, Climans T, Lillie E (2011) Childhood attention-deficit/hyperactivity disorder and future substance use disorders: Comparative Metaanalyses. J Am Acad Child Psy 50:9–21CrossRef

Cherkasova MV, Faridi N, Casey KF et al. (2014) Amphetamine-induced dopamine release and neurocognitive function in treatment-naïve adults with ADHD. Neuropsychopharmacology 39:1498–1507PubMedPubMedCentralCrossRef

Childress A, Hoo-Cardiel A, Lang P (2020) Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Exp Opin Pharmacotherapy 21:417–426CrossRef

Chouinard G, Annable L, Bradwein J (1984) An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83:126–128PubMedCrossRef

Chow R, Bruera E, Sanatani M et al. (2021) Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. BMJ Support Palliat Care. https://doi.org/10.1136/bmjspcare-2021-00324CrossRefPubMed

Christine CW, Garwood ER, Schrock LE, Austin DE, McCulloch CE (2010) Parkinsonism in patients with a history of amphetamine exposure. Mov Disord 25:228–231PubMedPubMedCentralCrossRef

Clemow DB (2017) Misuse of Methylphenidate. Curr Top Behav Neurosci 34:99–124PubMedCrossRef

Clemow DB, Bushe C, Mancini M, Ossipov MH, Upadhyaya H (2017) A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat 13:357PubMedPubMedCentralCrossRef

Coghill DR, Banaschewski T, Lecendreux M et al. (2014) Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. Eur Child Adolesc Psychiatry 23:61–68PubMedCrossRef

Connaughton M, Whelan R, O’Hanlon E, McGrath J (2022) White matter microstructure in children and adolescents with ADHD. Neuroimage Clin 33:102957PubMedPubMedCentralCrossRef

Coogan AN, Baird AL, Popa-Wagner A, Thome J (2016) Circadian rhythms and attention deficit hyperactivity disorder: The what, the when and the why. Prog Neuropsychopharmacol Biol Psychiatry 67:74–81PubMedCrossRef

Cooper WO, Habel LA, Sox CM et al. (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904PubMedPubMedCentralCrossRef

Conzelmann A, Müller S, Jans T et al. (2019) Long-term cardiovascular safety of psychostimulants in children with attention deficit/hyperactivity disorder. Int J Psychiatry Clin Pract 23:157–159PubMedCrossRef

Correll CU, Cortese S, Croatto G et al. (2021) Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry 20:244–275PubMedPubMedCentralCrossRef

Cortese S, Holtmann M, Banaschewski T et al. (2013) Pracitioner review: Current best practice in the management of adverse event during treatment with ADHD medications in children and adolescents. J Child Psychol Psyc 54:227–246CrossRef

Cortese S, Adamo N, Del Giovane C et al. (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5:727–738PubMedPubMedCentralCrossRef

Costa A, la Fougere C, Pogarell O et al. (2013) Impulsivity is related to striatal dopamine transporter availability in healthy males. Psychiatr Res Neuroimaging 211:251–256CrossRef

Cubillo A, Smith AB, Barrett N et al. (2014) Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex 24:174–185PubMedCrossRef

Curtin K, Fleckenstein AE, Keeshin BR et al. (2018) Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology 43:2548–2555PubMedPubMedCentralCrossRef

Dahl MJ, Mather M, Werkle-Bergner M (2022) Noradrenergic modulation of rhythmic neural activity shapes selective attention. Trends Cogn Sci 26:38–52PubMedCrossRef

Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH (2014) ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood – a naturalistic long-term follow-up study. Addict Behav 39:325–328PubMedCrossRef

Dark C, Homman-Ludiye J, Bryson-Richardson RJ (2018) The role of ADHD associated genes in neurodevelopment. Dev Biol 438:69–83PubMedCrossRef

Demontis D, Walters RK, Martin J et al. (2019) Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet 51:63–75PubMedCrossRef

Ding YS, Naganava M, Gallezot JD et al. (2014) Clincal doses of atomexetine significantly occupy norepinephrine and serotonin transports: implications on treatment of depression and ADHD. Neuroimage 86:164–171PubMedCrossRef

Dittmann RW, Cardo E, Nagy P et al. (2014) Treatment response and remission in a double-blind, randomized, head-to-head Study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with Attention-Deficit Hyperactivity Disorder. CNS Drugs 28:1059–1069PubMedPubMedCentralCrossRef

Drechsler R, Brem S, Brandeis D et al. (2020) ADHD: current concepts and treatments in children and adolescents. Neuropediatrics 51:315–335PubMedPubMedCentralCrossRef

Eban-Rothschild A, Appelbaum L, de Lecea L (2018) Neuronal mechanisms for sleep/wake regulation and modulatory drive. Neuropsychopharmacology 43:937–952PubMedPubMedCentralCrossRef

Efmova EV, Gainetdinov RR, Budygin EA, Sotnikova TD (2016) Dopamine transporter mutant animals: a translational perpective. J Neurogen 30:5–15CrossRef

Elia J, Glessner JT, Wang K et al. (2011) Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet 44:78–84PubMedPubMedCentralCrossRef

Ellison-Wright I, Ellison-Wright Z, Bullmore E (2008) Structural brain change in attention deficit hyperactivity disorder identified by meta-analysis. Bmc Psychiatry 8:51. https://doi.org/10.1186/1471-244X-8-51CrossRefPubMedPubMedCentral

El-Zein RA, Abdel-Rahman SZ, Hay MJ et al. (2005) Cytogenetic effects in children treated with methylphenidate. Cancer Lett 230:284–291PubMedCrossRef

European Medicines Agency (2010) Overview of comments received on „Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD)“. EMA/CHMP/EWP/431734/2008

Falkai P, Wittchen H-U, Döpfner M et al (2018) Diagnostisches und Statistisches Manual Psychischer Störungen DSMCrossRef

Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270PubMedPubMedCentralCrossRef

Faraone SV, Buitelaar J (2010) Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adoles Psy 19:353–364CrossRef

Faraone SV, Larsson H (2019) Genetics of attention deficit hyperactivity disorder. Mol Psychiatry 24:562–575PubMedCrossRef

Faraone SV, Perlis RH, Doyle AE et al. (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1313–1323PubMedCrossRef

Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006) Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 8:4

Faraone SV, Biederman J, Morley CP, Spencer TJ (2008) Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Psy 47:994–1009

Faraone SV, Po MD, Komolova M, Cortese S (2019) Sleep-associated adverse events during methylphenidate treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychiatry 80:19675CrossRef

Faraone SV, Banaschewski T, Coghill D et al. (2021) The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev 128:789–818PubMedPubMedCentralCrossRef

Farhat LC, Flores JM, Behling E et al. (2022) The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Mol Psychiatry. https://doi.org/10.1038/s41380-021-01391-9CrossRefPubMed

Frodl T, Skokauskas N (2012) Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiat Scand 125:114–126PubMedCrossRef

Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (2012) Striatal dopamine transporter alterations in ADHD: Pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiat 169:264–272PubMedCrossRef

Gainetdinov RR (2010) Strengths and limitations of genetic models of ADHD. Attent Def Hyp Disord 2:21–30CrossRef

Garnock-Jones KP, Keating GM (2009) Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 11:203–226PubMedCrossRef

Gatt JM, Burton KL, Williams LM, Schofield PR (2015) Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res 60:1–13PubMedCrossRef

Gelperin K, Phelan K (2006) Psychiatric adverse events associated with drug treatment of ADHD: review of postmarketing safety data. FDA Report PID DO50243. U.S. Food and Drug Administration

Gerlach M (2004) Pharmakologie von Methylphenidat. In: Schulte-Markwort M, Warnke A (Hrsg) Methylphenidat. Thieme, Stuttgart, S 5–13

Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84CrossRef

Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041PubMedCrossRef

Gerlach M, Grünblatt E, Lange KW (2013) Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system? Attent Def Hyp Disord 5:71–81CrossRef

Gerlach M, Dittmann RW, Egberts K et al. (2021) Stellungnahme der Arbeitsgruppe „Kinder- und jugendpsychiatrische Pharmakologie“ der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) e. V. zur Kombinationstherapie von Psychostimulanzien und Guanfacin. Psychopharmakotherapie 28:76–78

Ghuman JK, Ginsburg GS, Subramaniam G et al. (2001) Psychostimulants in preschool children with attention deficit/hyperactivity disorder: clinical evidence from a developmental disorder institution. J Am Acad Child Psy 40:516–524CrossRef

Gillberg C, Melander H, von Knorring AL et al. (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiat 54:857–864PubMedCrossRef

Graham J, Banaschewski T, Buitelaar J et al. (2011) European guidelines on managing adverse events of medication for ADHD. Eur Child Adoles Psy 20:17–37CrossRef

Groenman AP, Oosterlaan J, Rommelse N et al. (2013) Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study. Addiction 108:1503–1511PubMedCrossRef

Groenman AP, Janssen TW, Oosterlaan J et al. (2017) Childhood psychiatric disorders as risk factor for subsequent substance abuse: a meta-analysis. J Am Acad Chil Adol Psychiatry 56:556–569CrossRef

Grünblatt E, Bartl J, Walitza S (2018) Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways. Transl Psychiatry. https://doi.org/10.1038/s41398-018-0096-8CrossRefPubMedPubMedCentral

Grünblatt E, Werling AM, Roth A, Romanos M, Walitza S (2019) Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder. J Neural Transm 126:517–529PubMedCrossRef

de Haes UJ, Kortekaas R, Van Waarde A et al. (2005) Assessment of methylphenidate-induced changes in binding of continuously infused [¹¹C]-raclopride in healthy human subjects: correlation with subjective effects. Psychopharmacology 183:322–330CrossRef

Hammerness PG, Karampahtsis C, Babalola R, Alexander ME (2015) Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf 14:543–551PubMedCrossRef

Hannestad J, Gallezot JD, Planeta-Wilson B et al. (2010) Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans In vivo. Biol Psychiatr 68:854–860CrossRef

Harich B, van der Voet M, Klein M et al. (2020) From rare copy number variants to biological processes in ADHD. Am J Psychiatry 177:855–866PubMedCrossRef

Harris SS, Green SM, Kumar M, Urs NM (2022) A role for cortical dopamine in the paradoxical calming effects of psychostimulants. Sci Reports 12:3129

Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (2013) Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. Jama Psychiatry 70:185–198PubMedCrossRef

Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol 27:479–496PubMedPubMedCentralCrossRef

Her L, Zhu H-J (2020) Carboxylase 1 and precision pharmacotherapy: Pharmacogenetics and nongenetic regulators. Drug Metab Dispos 48:230–244PubMedPubMedCentralCrossRef

Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology – Update 2017. Pharmacopsychiatry 51:9–62PubMedCrossRef

Higgins GA, Silenieks LB, MacMillan C et al. (2020) Characterization of amphetamine, methylphenidate, nicotine, and atomoxetine on measures of attention, impulsive action, and motivation in the rat: implications for translational research. Front Pharmacol 11:427PubMedPubMedCentralCrossRef

Hirota T, Schwartz S, Correll CU (2014) Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adoles Psychiatry 53:153–173CrossRef

Hollis C, Chen Q, Chang Z et al. (2019) Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry 6:651–658PubMedPubMedCentralCrossRef

Hoogman M, Bralten J, Hiba DP et al. (2017) Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry 4:310–319PubMedPubMedCentralCrossRef

Hoogman M, Muetzel R, Guimaraes JP et al. (2019) Brain imaging of the cortex in ADHD: a coordinated analysis of large-scale clinical and population-based samples. Am J Psychiatry 176:531–542PubMedPubMedCentralCrossRef

Huang YS, Tsai MH (2011) Long-term outcomes with medications for attention-deficit hyperactivity disorder. Current status of knowledge. CNS Drugs 25:539–554PubMedCrossRef

Huss M, Poustka F, Lehmkuhl G, Lehmkuhl U (2008) No increase in long-term risk for nicotine use disorders after treatment with methyl-phenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study. J Neural Transm 115:335–339PubMedCrossRef

Huss M, Chen W, Ludolph AG (2016) Guanfacine extended release: a new pharmacological treatment option in Europe. Clin Drug Invest 36:1–25CrossRef

Huybrechts KF, Brpms G, Christensen LB et al. (2018) Association between bethylphenidate and amphetamine use in pregnancy and risk of congenital malformations a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 75:167–175PubMedCrossRef

Iversen II (1967) The uptake and storage of noradrenalin in symphathetic nerves. Cambridge University Press, Cambridge

Joshi G, Wilens T, Firmin ES, Hoskova B, Biederman J (2021) Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. J Psychopharmacol 35:203–210PubMedCrossRef

Kerdar MS, Scheuerpflug P, Srdinko P et al. (2007) Quantitative effect of treatment with methylphenidate on EEG – a pilot study. Z Kinder Jug Psych 35:247–255

Kim JS, Lee KH, Hwang CS, Kim JW (2022) Subcortical volumetric alterations as potential predictors of methylphenidate treatment response in youth with attention-deficit/hyperactivity disorder. J Psychiatry Neurosci 47:E11–E20PubMedPubMedCentralCrossRef

Kollins SH, Jain R, Rams M et al. (2011) Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 127:e1406–e1413PubMedPubMedCentralCrossRef

Kowalczyk OS, Cubillo AI, Smith A et al. (2019) Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol 29:1102–1116PubMedCrossRef

Kratochvil CJ, Wilens TE, Greenhill LL et al. (2006) Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Psy 45:919–927CrossRef

Krauel K, Feldhaus HC, Simon A et al. (2010) Increased echogenicity of the substantia nigra in children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiat 68:352–358PubMedCrossRef

Krause J (2008) SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 1:611-625CrossRef

Kuczenski R, Segal DS (1997) Effects of Methylphenidate on extracellular dopamine, serotonin, and norepinephine: comparison with amphetamine. J Neurochem 68:2032–2037PubMedCrossRef

Laruelle M, Abi-Dargham A, van Dyck CH et al. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182–1190PubMed

Leffa DT, Panzenhagen AC, Salvi AA et al. (2019) Systematic review and meta-analysis of the behavioral effects of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 100:166–179PubMedCrossRef

Lenzi F, Cortese S, Harris J, Masi G (2018) Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis. Neurosci Biobehav Rev 84:359–367PubMedCrossRef

Liang EF, Lim SZ, Tam WW et al. (2018) The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): systematic review, meta-analysis, and meta-regression. Int J Environ Res Public Health 15:1789PubMedPubMedCentralCrossRef

Lichtenstein P, Halldner L, Zetterqvist J et al. (2012) Medication for attention deficit–hyperactivity disorder and criminality. N Engl J Med 367:2006–2014PubMedPubMedCentralCrossRef

Liu H, Feng W, Zhang D (2019) Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adol Psychiatry 28:1283–1293CrossRef

Lukito S, Norman L, Carlisi C et al. (2020) Comparative Metaanalyses of brain structural and functional abnormalities during cognitive control in attention-deficit/hyperactivity disorder and autism spectrum disorder. Psychol Med 50:894–919PubMedPubMedCentralCrossRef

Madras BK, Miller GM, Fischman AJ (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiat 57:1397–1409PubMedCrossRef

Mahone EM, Crocetti D, Ranta ME et al. (2011) A preliminary neuroimaging study of preschool children with ADHD. Clin Neuropsychol 25:1009–1028PubMedCrossRef

Man KK, Coghill D, Chan EW et al. (2017) Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiatry 74:1048–1055PubMedPubMedCentralCrossRef

Man KK, Lau WC, Coghill D et al. (2020) Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study. Lancet Child Adolesc Health 4:435–443PubMedCrossRef

Mannuzza S, Klein RG, Truong NL et al. (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiat 165:604–609PubMedCrossRef

Martella D, Aldunate N, Fuentes LJ, Sánchez-Pérez N (2020) Arousal and executive alterations in attention deficit hyperactivity disorder (ADHD). Front Psychol. https://doi.org/10.3389/fpsyg.2020.01991CrossRefPubMedPubMedCentral

Mason GJ (1991) Stereotypies and suffering. Behav Processes 25:103–115PubMedCrossRef

Matthijssen AFM, Dietrich A, Bierens M et al. (2019) Continued benefits of methylphenidate in ADHD after 2 years in clinical practices: a randomized placebo-controlled discontinuation study. Am J Psychiatry 176:754–762PubMedCrossRef

McCarthy S, Neubert A, Man KK et al. (2018) Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry 18:1–10CrossRef

McCracken JT, McGough JJ, Loo SK et al. (2016) Combined stimulant and guanfacine administration in attention-deficit/hyperactivity disorder: a controlled, comparative study. J Am Aca Child Adol Psychiatry 55:657–666CrossRef

Mehler-Wex C, Riederer P, Gerlach M (2006) Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder. neurotox res 10:167–179PubMedCrossRef

Mechler K, Banaschewski T, Hohmann S, Häge A (2022) Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther 230:107940PubMedCrossRef

Michelson D, Buitelaar JK, Danckaerts M et al. (2004) Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adol Psychiatry 43:896–904CrossRef

Mills KL, Bathula D, Dias TG et al. (2012) Altered cortico-striatal-thalamic connectivity in relation to spatial working memory capacity in children with ADHD. Front Psychiatry 3:2. https://doi.org/10.3389/fpsyt.2012.00002CrossRefPubMedPubMedCentral

Mohamoud M, Chen Q, Croteau D et al. (2022) Acute hyperkinetic movement disorders as a multifactorial pharmacodynamic drug interaction between methylphenidate and risperidone in children and adolescents. J Clin Psychopharmacology 42:238–246CrossRef

Molina BSG, Hinshaw SP, Swanson JM et al. The MTA at 8 years. Prospective foolow-up of children treated for combined-type of ADHD in a multisite study. J Am Acad Child Psy 48:484–500

Moon SJ, Kim CJ, Lee YJ et al. (2014) Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD). PLoS ONE 9:e108918PubMedPubMedCentralCrossRef

Moran LV, Ongur D, Hsu J et al. (2019) Psychosis with methylphenidate or amphetamine in patients with ADHD. New Engl J Med 380:1128–1138PubMedCrossRef

MTA Cooperation Group (1999) A 14 month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment Study of Children with ADHD. Arch Gen Psychiat 56:1073–1086CrossRef

MTA Cooperation Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113:754–761CrossRef

Mueller A, Hong DS, Shepard S, Moore T (2017) Linking ADHD to the neural circuitry of attention. Trends Cog Sci 21:474–488CrossRef

Murphy TK, Fernandez TV, Coffey BJ et al. (2017) Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adol Psychopharmacol 27:762–770CrossRef

Myer N, Boland, Faraone S (2018) Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry 23:1929–1936PubMedCrossRef

Nageye F, Cortese S (2019) Beyond stimulants: a systematic review of randomized controlled trials assessing novel compounds for ADHD. Exp Rev Neurotherapeutics 19:707–717CrossRef

Nakao T, Radua J, Rubia K, Mataix-Cols D (2011) Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. Am J Psychiatry 168:1154–1163PubMedCrossRef

Newcorn JH, Kratochvil CJ, Allen AJ et al. (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. A J Psychiat 165:721–730CrossRef

Newcorn JH, Huss M, Connor DF et al. (2020) Efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Dev Behav Pediatr 41:565–570PubMedCrossRef

Nishitomi K, Yano K, Kobayashi M et al. (2018) Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α2A-adrenergic receptors in rats. Behav Brain Res 345:21–29PubMedCrossRef

Norman LJ, Carlisi C, Lukito S et al. (2016) Structural and functional brain abnormalities in attention-deficit/hyperactivity disorder and obsessive-compulsive disorder: a comparative meta-analysis. Jama Psychiatry 73:815–825PubMedCrossRef

Olazagasti MAR, Klein RG, Mannuzza S et al. (2013) Does childhood attention-deficit/hyperactivity disorder predict risk-taking and medical illnesses in adulthood? J Am Acad Child Psy 52:153–162CrossRef

Osland ST, Steeves TD, Pringsheim T (2018) Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007990.pub3CrossRefPubMedPubMedCentral

Patra S, Nebhinani N, Viswanathan A, Kirubakaran R (2019) Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis. Autism Res 12:542–552PubMedCrossRef

Pennick M (2010) Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsych Dis Treat 6:317–327CrossRef

Pievsky MA, McGrath RE (2018) The neurocognitive profile of attention-deficit/hyperactivity disorder: a review of metaanalyses. Arch Clin Neuropsychol 33:143–157PubMedCrossRef

Pliszka SR, Greenhill LL, Crismon ML et al. (2000) The Texas children’s medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part I and II. J Am Acad Child Psy 39:908–927CrossRef

Portela M, Rubiales AS, Centeno C (2011) The use of psychostimulants in cancer patienst. Curr Opin Supp Pall Care 5:164–168CrossRef

Preston RJ, Kollins SH, Swanson JM et al. (2005) Comments on ‚Cytogenetic effects in children treated with methylphenidate‘ by El-Zein et al. Cancer Lett 230:292–294PubMedCrossRef

Pringsheim T, Hirsch L, Gardner D, Gorman DA (2015) The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry 60:42–51PubMedPubMedCentralCrossRef

Quinn PD, Chang Z, Hur K et al. (2017) ADHD medication and substance-related problems. Am J Psychiatry 174:877–885PubMedPubMedCentralCrossRef

Reed VA, Buitelaar JK, Anand E et al. (2016) The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 30:603–628PubMedCrossRef

Ren W-W, Liu Y, Li B-M (2012) Stimulation of α2A-adrenoceptors promotes the maturation of dendritic spines in cultured neurons of the medial prefrontal cortex. Mol Cell Neurosci 49:205–216PubMedCrossRef

Riccardi P, Li R, Ansari MS et al. (2006) Amphetamine-induced displacement of [¹⁸F]fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacol 31:1016–1026CrossRef

Rodrigues R, Lai M-C, Beswick A et al. (2021) Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. J Child Psychol Psychiatry 62:680–700PubMedCrossRef

Romanos M, Weise D, Schliesser M et al. (2010) Abnormality of substantia nigra in attention-deficit/hyperactivity disorder. J Psychiatry Neurosci 35:55–58PubMedPubMedCentralCrossRef

Ronald A, de Bode N, Polderma TJ (2021) Systematic review: How the attention-deficit/hyperactivity disorder polygenic risk score adds to our understanding of ADHD and associated traits. J Am Acad Child Ado Psychiatry 60:1234–1277CrossRef

Rowley HL, Kulkarni RS, Gosden J et al. (2014) Differences in the neurochemical and behavioural profiles of lisdexamfetamine, methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats. J Psychopharmacol 28:254–269PubMedCrossRef

Ruggiero S, Clavenna A, Reale L et al. (2014) Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 24:1578–1590PubMedCrossRef

Sachse C, Brockmöller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284PubMedPubMedCentral

Sagvolden T (2006) The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct 2:1–7CrossRef

Sallee F, Connor DF, Newcorn JH (2013) A review of the rational and clinical utilization of a₂-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adol Psychop 23:308–319CrossRef

Samea F, Soluki S, Nejati V et al. (2019) Brain alterations in children/adolescents with ADHD revisited: A neuroimaging meta-analysis of 96 structural and functional studies. Neurosci Biobehav Rev 100:1–8PubMedPubMedCentralCrossRef

Scahill L, Chappell PB, Kim YS et al. (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiat 158:1067–1074PubMedCrossRef

Scahill L, McCracken JT, King BH et al. (2015) Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 172:1197–1206PubMedCrossRef

Schelleman H, Bilker WB, Strom BL et al. (2011) Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127:1102–1110PubMedPubMedCentralCrossRef

Schneider G, Banaschewski T, Feldman BL et al. (2019) Weight and height in children and adolescents with attention-deficit/hyperactivity disorder: A longitudinal database study assessing the impact of guanfacine, stimulants, and no pharmacotherapy. J Child Adoles Psychopharmacol. https://doi.org/10.1089/cap.2018.0132CrossRef

Schoretsanitis G, de Leon J, Eap CB, Kane JM, Paulzen M (2019) Clinically significant drug–drug interactions with agents for attention-deficit/hyperactivity disorder. CNS Drugs 33:1201–1222PubMedCrossRef

Schulte-Markwort M (2004) Methylphenidat – Zur Geschichte eines Medikaments. In: Schulte-Markwort M, Warnke A (Hrsg) Methylphenidat. Thieme, Stuttgart, S 1–4

Schulz KP, Fan J, Bedard ACV et al. (2012) Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 69:952–961PubMedCrossRef

Schwartz S, Correll CU (2014) Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adol Psychiatry 53:174–187CrossRef

Seppi K, Chaudhuri RK, Coelho M et al. (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 34:180–198PubMedPubMedCentralCrossRef

Shang C, Yan C, Lin H et al. (2016) Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med 46:3173–3185PubMedCrossRef

Shaw P, Eckstrand K, Sharp W et al. (2007) Attention-deficit/hyperactivity disorder is characterized by delay in cortical maturation. Proc Natl Acad Sci U S A 104:19649–19654PubMedPubMedCentralCrossRef

Shotbolt P, Tziortzi AC, Searle GE et al. (2012) Within-subject comparison of [11C]-(+)-PHNO and [11C] raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32:127-136PubMedCrossRef

Slifstein M, Kegeles LS, Xu X et al. (2010) Striatal and extrastriatal dopamine release measured with PET and [¹⁸F] fallypride. Synapse 64:350–362PubMedPubMedCentralCrossRef

Sobel LJ, Bansal R, Maia TV et al. (2010) Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder. Am J Psychiatry 167:977–986PubMedPubMedCentralCrossRef

Solmi M, Fornaro M, Ostinelli EG et al. (2020) Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 19:214–232PubMedPubMedCentralCrossRef

Sonuga-Barke EJS, Coghill D (2014) The foundations of next generation attention-deficit/hyperactivity disorder neuropsychology: building on progress during the last 30 years. J Child Psychol Psychiatry 55:e1–e5PubMedCrossRef

Spencer TJ, Biederman J, Wilens T et al. (1996) Pharmacotherapy of attention-deficit hyperactivity disorder accross the life cycle. J Am Acad Child Psy 35:409–432CrossRef

Spencer T, Biederman J, Heiligenstein J et al. (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adol Psychop 11:251–265CrossRef

Spencer T, Heiligenstein JH, Biederman J et al. (2002) Results from 2 proof-of-concept, placebo-controlled studies of in children with attention-deficit/hyperactivity disorder. J Clin Psychiat 63:1140–1147CrossRef

Spencer TJ, Salle FR, Gilbert DL et al. (2008) Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 11:470–481PubMedCrossRef

Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M (2012) Lisdexamfetamine dimesylate. A new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs 26:691–705PubMedCrossRef

Steiner H, van Waes V (2013) Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol 100:60–80PubMedCrossRef

Steinhausen H-C, Helenius D (2013) The association between medication for attention-deficit/hyperactivity disorder and cancer. J Child Adolesc Psychopharmacol 23:208–213PubMedCrossRef

Stopper H, Walitza S, Warnke A, Gerlach M (2008) Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate. J Neural Transm 115:331–334PubMedCrossRef

Sturman N, Deckx L, van Driel ML (2017) Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011144.pub2CrossRefPubMedPubMedCentral

Sukmajaya AC, Lusida MI, Setiawati S, Setiawati Y (2021) Systematic review of gut microbiota and attention-deficit hyperactivity disorder (ADHD). Ann Gen Psychiatry 20:12PubMedPubMedCentralCrossRef

Sun Z, Murry DJ, Sanghani SP et al. (2004) Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 310:469–476PubMedCrossRef

Sun C-K, Tseng P-T, Wu C-K et al. (2019) Therapeutic effects of methylphenidate for attention-deficit/hyperactivity disorder in children with borderline intellectual functioning or intellectual disability: A systematic review and meta-analysis. Sci Rep 9:1–10

Sundquist J, Ohlsson H, Sundquist K, Kendler K (2015) Attention-deficit/hyperactivity disorder and risk for drug use disorder: a population-based follow-up and co-relative study. Psychol Med 45:977–983PubMedCrossRef

Sutcubasi B, Metin B, Kurban MK et al. (2020) Resting-state network dysconnectivity in ADHD: A system-neuroscience-based meta-analysis. World J Biol Psychiatry 21:662–672PubMedCrossRef

Tourette’s Syndrome Study Group (2002) Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 58:527–536CrossRef

Trendelenburg U (1963) Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines. Pharmacol Rev 15:225–276PubMed

Treuer T, Mendez L, Montgomery W, Wu S (2016) Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review. Neuropsych Dis Treatm 12:1061CrossRef

Treur JL, Demontis D, Smith GD et al. (2021) Investigating causality between liability to ADHD and substance use, and liability to substance use and ADHD risk, using Mendelian randomization. Addic Biol 26:e12849CrossRef

Tucha O, Prell S, Mecklinger L et al. (2006) Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder. Psychopharmacology 185:315–326PubMedCrossRef

Tucker JD, Suter W, Petibone DM et al. (2009) Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutat Res 677:53–58PubMedCrossRef

Vaidya CJ, Austin G, Kirkorian G et al. (1998) Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci 95:14494–14499PubMedPubMedCentralCrossRef

Valera EM, Faraone SV, Murray KE, Seidman LJ (2007) Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry 61:1361–1369PubMedCrossRef

Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28:783–800PubMedCrossRef

van Elst LT, Maier S, Klöppel S et al. (2016) The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. J Psychiatry Neorosci 41:422-430CrossRef

Van Stralen JP (2020) A controlled trial of extended-release guanfacine and psychostimulants on executive function and ADHD. J Attent Disord 24:318–325CrossRef

Van Zwieten P, Thoolen M, Timmermans PB (1984) The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 6:II28PubMed

Vaughan B, Kratochvil CJ (2012) Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 21:941–955PubMedCrossRef

Ventura P, de Giambattista C, Spagnoletta L et al. (2020) Methylphenidate in autism spectrum disorder: a long-term follow up naturalistic study. J Clin Med 9:2566PubMedPubMedCentralCrossRef

Verrotti A, Moavero R, Panzarino G et al. (2018) The challenge of pharmacotherapy in children and adolescents with epilepsy-ADHD comorbidity. Clin Drug Investig 38:1–8

Vilar-Ribó L, Sánchez-Mora C, Rovira P et al. (2021) Genetic overlap and causality between substance use disorder and attention-deficit and hyperactivity disorder. Am J Med Genet Part B Neuropsychiatr Genet 186:140–150CrossRef

Vitiello B (2001) Long-term effects of stimulant medication on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adol Psychop 11:25–34CrossRef

Vitiello B, Elliott GR, Swanson JM et al. (2012) Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiat 169:167–177PubMedCrossRef

Volkow ND, Wang GJ, Fowler JS et al. (1999) Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 65:PL7–PL12PubMedCrossRef

Volkow ND, Wang G-J, Fowler JS et al. (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human bran. J Neurosci 21:RC121–RC125PubMedPubMedCentralCrossRef

Volkow ND, Wang GJ, Fowler JS et al. (2004) Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiat 161:1173–1180PubMedCrossRef

Walhovd KB, Amlien I, Schrantee A et al. (2020) Methylphendate effects on cortical thickness in children and adults with attention-deficit/hyperactivity disorder: a randomized trial. Am J Neuroradiology 41:758–771CrossRef

Walitza S, Melfsen S, Herhaus G et al. (2007a) Association of Parkinson’s disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm 72(Suppl):311–315

Walitza S, Werner B, Romanos M et al. (2007b) Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? Environ Health Persp 115:936–940CrossRef

Walitza S, Kampf K, Oli RG et al. (2010) Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. Toxicol Lett 193:4–8PubMedCrossRef

Wang Y, Zuo C, Xu Q, Hap L, Zhang Y (2020) Attention-deficit/hyperactivity disorder is characterized by a delay in subcortical maturation. Prog Neuropsychopharmacol Biol Psychiatry 104:110044PubMedCrossRef

Waxmonsky JG, Pelham WE, Campa A et al. (2020) Randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 59:1330–1341PubMedCrossRef

Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH (2013) Systematic review: pharmacological treatment of tic disorders – efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav R 37:1162–1171CrossRef

Wernicke JF, Holdridge KC, Jin L et al. (2007) Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 49:498–502PubMedCrossRef

Wiggs KK, Chang Z, Quinn PD et al. (2018) Attention-deficit/hyperactivity disorder medication and seizures. Neurology 90:e1104–e1111PubMedPubMedCentralCrossRef

Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185PubMedCrossRef

Wilens TE, Bukstein O, Brams M et al. (2012) A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Psy 51:74–85CrossRef

Wimberley T, Agerbo E, Horsdal HT et al. (2020) Genetic liability to ADHD and substance use disorders in individuals with ADHD. Addiction 115:1368–1377PubMedCrossRef

Wirtz MA (2021) Dorsch – Lexikon der Psychologie, 20. Aufl. Hogrefe, Göttingen

Witcher JW, Long A, Smith B et al. (2003) Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adol Psychop 13:53–63CrossRef

Witt KL, Shelby MD, Itchon-Ramos N et al. (2008) Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. J Am Acad Child Adolesc Psychiatry 47:1375–1383PubMedPubMedCentralCrossRef

World Health Organisation (2022) ICD-11: International classification of diseases, 11. Aufl.

Wu J, Xiao H, Sun H, Zou L, Zhu L-Q (2012) Role of dopamine receptors in ADHD: a systematic meta-analysis. Mol Neurobiol 45:605–620PubMedCrossRef

Yuan D, Zhang M, Huang Y et al. (2021) Noradrenergic genes polymorphisms and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. Medicine 100(46):e27858PubMedPubMedCentralCrossRef

Zhou MS, Nasir M, Farhat LC et al. (2021) Meta-analysis: pharmacologic treatment of restricted and repetitive behaviors in autism spectrum disorders. J Am Acad Child Adol Psychiatry 60:35–45CrossRef

Faraone SV, Banaschewski T, Coghill D et al. (2021) The world federation of ADHD international consensus statement: 208 evidenced-based conclusions about the disorder. Neurosci Biobehav Rev 128:789–818PubMedPubMedCentralCrossRef

Gerlach M, Romanos M (2014) Attention-deficit/hyperactivity disorder (ADHD). In: Baumann Ch, Wolters E (Hrsg) Parkinson disease and other movement disorders. State of the art. VU University Press, Amsterdam, S 705–714

Iversen L (Hrsg) (2006) Speed, ecstasy, ritalin. The science of amphetamines. University Press, Oxford

Titel: Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden
verfasst von: Prof. Dr. med. Dipl. Psych. Susanne Walitza
Dr. rer. nat. Lukasz Smigielski
Prof. Dr. rer. nat. Manfred Gerlach
Verlag: Springer Berlin Heidelberg
Buch: Neuro-/Psychopharmaka im Kindes- und Jugendalter
Print ISBN: 978-3-662-65266-4

Electronic ISBN: 978-3-662-65267-1

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-65267-1_8

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).